Details

Guidance to Establish Equivalence or Relative Potency of Safety and Efficacy of a Second Entry Short-Acting Beta2-Agonist Metered Dose Inhaler (MDI) [Health Canada, 1999] - Canada.ca

Metadata and links for an archived snapshot.

Source: Health Canada
Date: Jan 6, 2026 · edition #6
Timestamp: 2026-01-06T18:56:40.917Z
Language: en
Original URL: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/inhalers/guidance-establish-equivalence-relative-potency-safety-efficacy-second-entry-short-acting-beta2-agonist-metered-dose-inhaler.html?wbdisable=true
Replay URL: https://replay.healtharchive.ca/job-6/20260106185640/https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/inhalers/guidance-establish-equivalence-relative-potency-safety-efficacy-second-entry-short-acting-beta2-agonist-metered-dose-inhaler.html?wbdisable=true#ha_snapshot=482352
ID: 482352
Status: 200
Type: text/html

Independent archive · Not an official government website. For up-to-date recommendations, always consult the official source website.

Other snapshots